The KEYNOTE-189 exploratory analysis demonstrated that triplet pembrolizumab-pemetrexed-platinum (irrespective of PD-L1 expression) therapy “should be considered as a standard first-line treatment for patients with metastatic non-squamous NSCLC, regardless of KRAS mutation status” [72]. This evidence concerns the gene KRAS and non-small cell lung carcinoma.